Epithelial cell adhesion molecule (EpCAM) is a highly expressed antigen in various solid tumors including, colorectal, gastric, head and neck and ovarian cancers, which holds a critical position in tumor progression process.
AM-928 is a novel humanized therapeutic antibody, which can induce tumor cell apoptosis or inhibit tumor cell stemness and metastasis by inhibiting EpCAM downstream signaling cascade. The in vitro studies showed that AM-928 is effective in targeting a broad range of EpCAM-expressing cancers. The in vivo studies have demonstrated AM-928’s ability to suppress tumor growth or metastasis and suggest that AM-928 could be an effective treatment against EpCAM-expressed solid tumors.
The IND-enabling program of AM-928 in the US and Taiwan has been initiated and the clinical investigations on solid tumors is expected in early 2023.
